Internal Med Medical News

Your Unread Messages

See All

Hello, Mary O'connor
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy
Annals of Oncology, 11/06/09

Ennishi D et al. – A recent laboratory study indicated that statins impaired the antitumor effects of rituximab by inducing conformational changes in CD20. Although these findings raised significant concerns about statin use during rituximab treatment, their clinical significance is unclear. The results of this study indicate that statins do not influence the clinical prognosis of DLBCL treated with RCHOP.

Methods

Retrospective study investigating effects of statins on prognosis of diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP)
Newly diagnosed DLBCL patients analyzed (n = 256), including 35 patients taking statins

Results

3-year PFS rates 84% and 73% , while the overall survival rates were 89% and 78% for those patients treated with and without statins, respectively
After adjusting for International Prognostic Index and serum cholesterol level, statin use is not associated with prognosis

<< Previous
Citrulline dependence of anti-cyclic citrullinated peptide...

Next >>
The specificity of neuroprotection by antioxidants